Strongbridge Biopharma (NASDAQ:SBBP) announced that it intends to offer and sell 5 million of its ordinary shares in an underwritten public offering. As quoted in the press release: The Company intends to use the net proceeds from the offering for investment in commercial infrastructure for its two commercial products, Keveyis and Macrilen, continued development of …

Strongbridge Biopharma (NASDAQ:SBBP) announced that it intends to offer and sell 5 million of its ordinary shares in an underwritten public offering.
As quoted in the press release:

The Company intends to use the net proceeds from the offering for investment in commercial infrastructure for its two commercial products, Keveyis and Macrilen, continued development of its clinical-stage product candidates, Recorlev and veldoreotide, and for other general corporate purposes, which may include working capital, capital expenditures, acquisition of additional technologies or other forms of intellectual property, acquisition of assets or businesses that are complementary to its existing business, and general and administrative expenses.

Click here to read the full press release.